Oral treatment is being developed to treat autoimmune uveitis.
Enzo Biochem signed a cooperative R&D agreement with the NIH’s National Eye Institute, centered on carrying out a proof-of-concept clinical trial of Optiquel™, Enzo’s oral therapeutic for chronic autoimmune uveitis.
Enzo will supply the compound and fund a portion of the studies. The agreement with the National Eye Institute also covers nonclinical research into the use of compounds to enhance the immune-mediated oral tolerance response to specific antigens.
Enzo says that this work may have applications across its whole immune regulation platform including its Crohn’s disease candidate, Alequel™, and EGS21™, which is in development for treating nonalcoholic steatohepatitis. Enzo most recently reported positive results from a Phase II trial with Alequel in patients with moderate-to-severe Crohn’s disease.